Administration of IFNα2 during chronic HIV infection tends to decrease HIV RNA and p24 antigen levels but is by no means a panacea as it has yet to be shown that it improves clinical outcomes beyond antiretroviral therapy (ART) alone [7, 16, , , , , , , , , , –27]. This evidence concerns the gene IFNA2 and HIV infectious disease.